SARS-CoV-2灭活疫苗(Vero细胞)皮内免疫猕猴的临床前安全性评价
该研究在恒河猴中评价SARS-CoV-2灭活疫苗(Vero细胞)皮内接种的临床前安全性。结果显示除局部接种部位反应外,一般临床状况、摄食量、体重及眼科检查无明显异常,血液学、骨髓影像、血清生化及尿常规指标有不同程度波动但无剂量-反应或时间-反应相关性,中和抗体和ELISpot结果表明可诱导较强的体液和细胞免疫,中和抗体水平随剂量和时间呈一定趋势。
要点
- 恒河猴皮内接种SARS-CoV-2灭活疫苗后除局部接种部位反应外,一般临床状况、摄食量、体重及眼科检查无明显异常。
- 血液学、骨髓影像、血清生化及尿常规指标各组给药后有不同程度波动,但无剂量-反应或时间-反应相关性。
- 中和抗体和ELISpot结果表明接种后可诱导较强的体液和细胞免疫,中和抗体水平随剂量和时间呈一定趋势。
核心结论
- 恒河猴皮内接种SARS-CoV-2灭活疫苗的重复给药毒性试验显示良好的安全性和免疫原性。
研究设计与样本
- 在恒河猴中开展SARS-CoV-2灭活疫苗(Vero细胞)皮内接种的临床前安全性评价,包含重复给药毒性试验。
主要发现
- 除局部接种部位反应外,一般临床状况、摄食量、体重及眼科检查无明显异常。
- 血液学、骨髓影像、血清生化及尿常规各项指标各组给药后有不同程度波动,但无剂量-反应或时间-反应相关性。
- 中和抗体和ELISpot结果表明接种后可诱导较强的体液和细胞免疫,中和抗体水平随剂量和时间呈一定趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) is an acute and highly pathogenic infectious disease in humans caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Six months after immunization with the SARS-CoV-2 vaccine, however, antibodies are almost depleted. Intradermal immunization could be a new way to solve the problem of nondurable antibody responses against SARS-CoV-2 or the poor immune protection against variant strains. We evaluated the preclinical safety of a SARS-CoV-2 vaccine for intradermal immunization in rhesus monkeys. The results showed that there were no obvious abnormalities in the general clinical condition, food intake, body weight or ophthalmologic examination except for a reaction at the local vaccination site. In the hematology examination, bone marrow imaging, serum biochemistry, and routine urine testing, the related indexes of each group fluctuated to different degrees after administration, but there was no dose-response or time-response correlation. The neutralization antibody and ELISpot results also showed that strong humoral and cellular immunity could be induced after vaccination, and the levels of neutralizing antibodies increased with certain dose- and time-response trends. The results of a repeated-administration toxicity test in rhesus monkeys intradermally inoculated with a SARS-CoV-2 inactivated vaccine showed good safety and immunogenicity.
引用
- Yang J, Huo X, Jiang Q, et al. Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques. Vaccine. 2023. PMID: 37003910. doi:10.1016/j.vaccine.2023.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。